Naftidrofuryl

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of naftidrofuryl
Mixture of four stereoisomers , structural formula without stereochemistry
General
Non-proprietary name Naftidrofuryl
other names

( RS ) -2- (Diethylamino) ethyl 3- (1-naphthyl) -2- (tetrahydrofuran-2-ylmethyl) propanoate

Molecular formula C 24 H 33 NO 3
External identifiers / databases
CAS number
  • 31329-57-4
  • 3200-06-4 (naftidrofuryl hydrogen oxalate)
ECHA InfoCard 100.045.960
PubChem 4417
Wikidata Q425867
Drug information
ATC code

C04 AX21

properties
Molar mass
  • 383.52 g mol −1
  • 473.6 g mol −1 (naftidrofuryl hydrogen oxalate)
Physical state

firmly

Melting point

110–111 ° C (naftidrofuryl hydrogen oxalate)

solubility

Easily soluble in water and ethanol (96%) (naftidrofuryl hydrogen oxalate)

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
07 - Warning

Caution

H and P phrases H: 302
P: ?
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Naftidrofuryl is a drug from the group of substances that promote blood circulation. It is used in peripheral arterial occlusive disease (PAOD) from stage II to improve the blood circulation in the legs and thus to extend the walking distance.

Use in medicine

According to the guideline of the German Society for Angiology , Naftidrofuryl or Nafronyl should be used to improve blood circulation. From a pharmacological point of view, however, there are doubts about the effectiveness of the agents that promote blood circulation, since the dilation of healthy vessels as a so-called steal phenomenon can further reduce the blood flow in the affected vessels.

Stereochemistry

Naftidrofuryl contains two stereocenters, so there are four stereoisomers of this drug:

  • ( R , R ) -isomer, enantiomer of the ( S , S ) -isomer

  • ( S , S ) -isomer, enantiomer of the ( R , R ) -isomer

  • ( R , S ) -isomer, diastereomer of the ( S , S ) -isomer

  • ( S , R ) -isomer, diastereomer of the ( S , S ) -isomer

Individual evidence

  1. ^ The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1099, ISBN 978-0-911910-00-1 .
  2. ↑ European Pharmacopoeia, Deutscher Apotheker Verlag Stuttgart, 6th edition, 2008, pp. 3342–3344, ISBN 978-3-7692-3962-1 .
  3. ↑ Registration dossier on naftidrofuryl ( GHS section ) at the European Chemicals Agency (ECHA), accessed on July 8, 2020.
  4. ↑ Holger Lawall, P. Huppert, G. Rümenapf: S3 guidelines for diagnosis, therapy and aftercare of peripheral arterial occlusive disease (PAD) . In: AWMF Register No. 065/003 development stage 3 . September 30, 2015.
  5. ↑ Klaus Aktories, Ulrich Förstermann, Franz Hofmann, Klaus Starke: General and special pharmacology and toxicology , 10th edition, Elsevier, Urban & Fischer, Munich; Jena 2009, ISBN 978-3-437-42522-6 .